The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Ifosfamide improved event-free and overall survival.
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Patient age and tumor site were linked to the risk of local recurrence, and histological response to neoadjuvant chemotherapy was tied to the risk of new metastatic disease.
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.
Children prescribed a medication containing a phthalate had a 19% higher risk of developing any childhood cancer.
Black individuals had the highest incidence of osteosarcoma, but the worst survival was seen in American Indian/Alaska Native individuals.
Researchers compared patients with giant cell tumor of the bone who were treated with surgery alone or surgery plus preoperative denosumab.
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
Researchers describe the development and validation of a risk-stratification system that uses clinicopathologic factors not included in a traditional TNM staging system.
There were no significant differences between the treatment groups in rates of surgical site infections, unplanned operations, oncologic events, or all-cause mortality.
Less than 10% of radiotherapy recommendations in 2020 NCCN guidelines were category 1 recommendations.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.